Nanotherapeutics awarded two BARDA task orders
These orders have the potential to serve the FDA and the Department of Health and Human Services (HHS) to mitigate shortages of critical medications and other treatments that have little or no availability in the current pharmaceutical market. The task orders awarded to the company in the last 18 months included the process of validation through the FDA.
If the company is successful in development of the drugs and if they receive FDA and Center for Drug Evaluation and Research (CDER) approval, they could be used to increasing fill and finishing manufacturing capacity for each respective product.
In 2013, BARDA established the Fill-Finish Manufacturing Network (FFMN) to address the need of production and clinical investigations for various medical conditions and to facilitate the national ability to produce vaccines for influenza in the case of a pandemic. During that time, the company was awarded four task orders to meet the need of mass influenza vaccine production and the production of other health emergency products.